WaveMan
WaveMan · Company
RAPP · Rapport Therapeutics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

RAPP Rapport Therapeutics (RAPP) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0002012593
Quote by TradingView
Cluster · 6 insidersC-suite buying · 1Form 144 · 5
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
86
13F, latest reported quarter

What the filings say about RAPP

Insiders, 180 days
-$23.6M net sold
6 buyers · 5 sellers · 44% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$4.0M
5 notices

Rapport Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Rapport Therapeutics, Inc. insiders sold a net $23.6M of stock across 123 Form 4 purchases and sales, with 6 insiders buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Sanchez Ramiro
Director
BUY
2026-10-23 SEC
3,600
$98.5K
n/a
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 100.0% of the 3,600 shares held after it.
  • 5 other insiders bought within 30 days.
  • 86 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Sanchez Ramiro bought about $98.5K of RAPP on Oct 23, 2026; 5 other insiders bought within 30 days and 86 funds added in the latest 13F quarter.
PAUL STEVEN M
Director
BUY
2026-10-22 SEC
35,714
$974.3K
n/a
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Sep 12, 2025.
  • The trade is 46.2% of the 77,380 shares held after it.
  • 5 other insiders bought within 30 days.
  • 86 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director PAUL STEVEN M bought about $974.3K of RAPP on Oct 22, 2026, the largest insider purchase at the company since 2024; 5 other insiders bought within 30 days and 86 funds added in the latest 13F quarter.
MARAGANORE JOHN
Director
BUY
2026-10-22 SEC
8,239
$217.3K
n/a
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 100.0% of the 8,239 shares held after it.
  • 5 other insiders bought within 30 days.
  • 86 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director MARAGANORE JOHN bought about $217.3K of RAPP on Oct 22, 2026, the largest insider purchase at the company since 2025; 5 other insiders bought within 30 days and 86 funds added in the latest 13F quarter.
MARAGANORE JOHN
Director
BUY
2026-10-22 SEC
1,172
$31.5K
n/a
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 12.5% of the 9,411 shares held after it.
  • 5 other insiders bought within 30 days.
  • 86 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director MARAGANORE JOHN bought about $31.5K of RAPP on Oct 22, 2026; 5 other insiders bought within 30 days and 86 funds added in the latest 13F quarter.
Silva Paul M
Director
BUY
2026-10-22 SEC
3,680
$99.6K
n/a
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 100.0% of the 3,680 shares held after it.
  • 5 other insiders bought within 30 days.
  • 86 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Silva Paul M bought about $99.6K of RAPP on Oct 22, 2026; 5 other insiders bought within 30 days and 86 funds added in the latest 13F quarter.
123 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 118 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$23.6M over 180 days
-$5.3M over 90 days · -$17.2M of it by a 10%+ holder
below 89% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
86 funds bought in last quarter
more than 63% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
9.9% of the float short (float per yahoo 2026-10-26) · 4.8 days to cover · settled 2026-09-30
more than 59% of Pharma & Biotech
What changed in the last 30 days
Oct 22Director PAUL STEVEN M bought $974.3K (Oct 22)
Oct 22Director MARAGANORE JOHN bought $248.9K (Oct 22)
Oct 6Officer Abraham N. Ceesay filed to sell $1.2M by Oct 6 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 1Chief Operating Officer Gault Cheryl sold $331.9K under a 10b5-1 plan (Sep 30)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Sep 30Officer CHERYL GAULT filed to sell $330.2K by Sep 30 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.

Watch RAPP

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+4.1%12M
-2%+36%+73%+111%2025-102025-122026-022026-042026-062026-082026-10 2026-04-17 · Third Rock Ventures VI, L.P. sold $17.2M2026-05-07 · Third Rock Ventures VI, L.P. sold $10.9M2026-05-11 · Third Rock Ventures V, L.P. sold $5.4M2026-08-25 · Yeleswaram Krishnaswamy sold $1.0M2026-10-22 · PAUL STEVEN M bought $974.3K2026-08-25 · Ceesay Abraham sold $938.0K2026-08-11 · Ceesay Abraham sold $936.8K2026-08-25 · Yeleswaram Krishnaswamy sold $827.2K2026-04-17 · Yeleswaram Krishnaswamy sold $808.8K2026-05-26 · Third Rock Ventures V, L.P. sold $743.8K2026-08-24 · Yeleswaram Krishnaswamy sold $658.0K2026-08-10 · Ceesay Abraham sold $651.5K2026-08-10 · Ceesay Abraham sold $391.3K2026-04-14 · Yeleswaram Krishnaswamy sold $357.8K2026-09-08 · Ceesay Abraham sold $325.3K2026-04-13 · Yeleswaram Krishnaswamy sold $320.5K2026-03-25 · Yeleswaram Krishnaswamy sold $303.3K2026-06-29 · Ceesay Abraham sold $292.1K2026-08-11 · Ceesay Abraham sold $281.7K2026-09-30 · Gault Cheryl sold $261.8K2025-12-15 · Bredt David sold $230.7K2026-01-15 · Bredt David sold $222.7K2026-07-14 · Ceesay Abraham sold $217.7K2026-10-22 · MARAGANORE JOHN bought $217.3K2026-05-08 · Third Rock Ventures VI, L.P. sold $202.3K2026-03-30 · Gault Cheryl sold $200.8K2025-12-31 · Bredt David sold $197.3K2026-08-11 · Ceesay Abraham sold $171.8K2026-06-30 · Gault Cheryl sold $157.0K2026-02-17 · Bredt David sold $156.3K2026-01-20 · Ceesay Abraham sold $152.4K2025-11-26 · Gault Cheryl sold $150.5K2026-10-21 · Ignelzi Troy A. bought $143.6K2026-06-30 · Gault Cheryl sold $139.5K2025-11-17 · Bredt David sold $135.7K2026-01-20 · Ceesay Abraham sold $132.7K2026-07-14 · Ceesay Abraham sold $110.7K2026-10-06 · Ceesay Abraham sold $108.1K2026-02-18 · Ceesay Abraham sold $103.2K2026-10-22 · Young Wendy B. bought $100.0K2026-10-22 · Silva Paul M bought $99.6K2026-10-23 · Sanchez Ramiro bought $98.5K2026-10-06 · Abraham N. Ceesay filed to sell $1.2M2026-09-30 · CHERYL GAULT filed to sell $330.2K2026-08-25 · KRISHNASWAMY YELESWARAM filed to sell $1.8M2026-08-24 · KRISHNASWAMY YELESWARAM filed to sell $553.4K2026-08-19 · KRISHNASWAMY YELESWARAM filed to sell $102.5K2026-06-30 · CHERYL GAULT filed to sell $403.9K2026-06-29 · Abraham N. Ceesay filed to sell $4.0M
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns RAPP: institutional holders (13F)

13F holdings, latest reported quarter
FMR LLC
7,172,894 sh
$298.9M
TRV GP V, LLC
6,280,525 sh
$261.7M
ARCH Venture Management, LLC
3,728,738 sh
$155.4M
Capital International Investors
2,921,958 sh
$121.8M
GOLDMAN SACHS GROUP INC
2,910,449 sh
$121.3M

Congress trades in RAPP

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

RAPP planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Abraham N. Ceesay
Filed 2026-10-06
$1.2M
CHERYL GAULT
Filed 2026-09-30
$330.2K
KRISHNASWAMY YELESWARAM
Filed 2026-08-25
$1.8M
KRISHNASWAMY YELESWARAM
Filed 2026-08-24
$553.4K
KRISHNASWAMY YELESWARAM
Filed 2026-08-19
$102.5K

RAPP mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF
$6.2M position · as of 2026-06-30
1.4%
PROFUND VP PHARMACEUTICALS
$160.6K position · as of 2026-06-30
1.4%
ALPS Medical Breakthroughs ETF
$1.9M position · as of 2026-05-31
1.2%
Direxion Daily Pharmaceutical & Medical Bull 3X Shares
$217.7K position · as of 2026-07-31
1.1%
Lord Abbett Micro-Cap Growth Fund
$1.7M position · as of 2026-07-31
0.8%
Virtus Biotech Clinical Trials Etf
$331.7K position · as of 2026-07-31
0.7%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
5 registered trials, 3 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
3
Phase 2
1 active
2
Phase 3
2 active
What changed recently
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I
2026-10-27 · Active Not Recruiting → Completed
Phase 2
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
6 insiders reported buying shares.
The record shows a net $23.6M sold by insiders over 180 days, 86 funds added last quarter, $4.0M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

RAPP financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$97.1M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-40.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-36.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-43.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-7.8%
TTM free cash flow over market value at close 2026-10-23
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-12
Operating income-$125.1M-$83.1M-$36.2M
Net income-$111.5M-$78.3M-$34.8M
EPS (diluted)-2.86-3.78-23.10
Operating cash flow-$87.5M-$64.8M-$27.2M
Cash$52.6M$56.8M$70.2M
SEC XBRL, fiscal years, as known on 2026-10-27

RAPP Stock Sonar score 4/7 axes

Find similar shapesCompare

RAPP ranks highest on institutional and government (63rd percentile) and risk and compliance (61st), and lowest on insider conviction (54th), among Pharma & Biotech peers.

Profitability
57
Inputs
  • Return on equity-40.0% · 60 pct, sector of 545
  • Return on assets-36.8% · 56 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-43.6% · 56 pct, sector of 576
Insider conviction
54
Inputs
  • Net Form 4 buying (codes P and S), 180d-$19.1M · 10 pct, sector of 428
  • Insider buyers, 180d6 · 97 pct, sector of 437
Institutional and government
63
Inputs
  • Funds adding, latest quarter86 · 63 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
61
Inputs
  • Short interest, % of float+9.9% · 40 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+5.0% · 82 pct, sector of 511
3 not measured: Financial health, Growth, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

RAPP filings, in plain words

Are Rapport Therapeutics insiders buying or selling RAPP?

In the 180 days to 2026-10-27, Rapport Therapeutics insiders were net sellers, a net $23.6M: $1.7M of purchases and $25.3M of sales reported on Form 4, by 6 buyers and 5 sellers.

Are there planned insider sales of RAPP?

Yes. 5 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $4.0M of stock; the latest, by Abraham N. Ceesay, was filed 2026-10-06.

Read the full summary

In the 180 days to 2026-10-27, Rapport Therapeutics insiders were net sellers of RAPP, a net $23.6M across purchases and sales reported on Form 4 by 6 buyers and 5 sellers. Most of that figure, $17.2M, came from a holder of 10% or more rather than an officer or director. Sales outweighed purchases more than tenfold by value. 6 different insiders reported purchases within the last 90 days, a cluster buy, which is rarer than a single purchase. 44% of the 34 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 5 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $4.0M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies